Managers / Q1 2026
Ishara Investments LP
CIK 0002111609 · 8929 EXPOSITION BLVD., LOS ANGELES, CA, 90034 · (818) 983-4448
Summary
Ishara Investments LP reported $106M in U.S.-listed holdings across 37 positions for Q1 2026.
Its largest position, PRAX, represents 6.9% of the portfolio.
Compared with Q4 2025, the fund opened 17 new positions and exited 19.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 92.6% · $98M
- ADR · 4.8% · $5M
- Other · 2.6% · $3M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AXSMAXSOME THERAPEUTICS INC. | NEW | +41.0K | 41.0K | +$7M | $7M |
| 4XC1KALVISTA PHARMACEUTICALS INC | NEW | +276.8K | 276.8K | +$6M | $6M |
| ARWRARROWHEAD PHARMACEUTICALS IN | NEW | +55.4K | 55.4K | +$3M | $3M |
| VERAVERA THERAPEUTICS INC | NEW | +82.0K | 82.0K | +$3M | $3M |
| TVTXTRAVERE THERAPEUTICS INC | NEW | +110.7K | 110.7K | +$3M | $3M |
| MLTXMOONLAKE IMMUNOTHERAPEUTICS | NEW | +174.3K | 174.3K | +$3M | $3M |
| SRRKSCHOLAR ROCK HLDG CORP | NEW | +57.4K | 57.4K | +$3M | $3M |
| ARDXARDELYX INC | NEW | +451.0K | 451.0K | +$3M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
Filing History
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.